Fred Saad

Ebp1 expression in benign and malignant prostate (2008)

Gannon, Philippe O, Koumakpayi, Ismaël, Le Page, Cécile, Karakiewicz, Pierre I, Mes-Masson, Anne-Marie, Saad, Fred

Abstract Background ErbB3-binding protein 1 (Ebp1) is a member of the PA2G4 family of proliferation-regulated proteins that is expressed in multiple malignant and non-malignant cells. ErbB3 and other...

Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors (2005)

Brown, Janet E., Cook, Richard J., Major, Pierre, Lipton, Allan, Saad, Fred, Smith, Matthew, ...

Background: Whether bone markers have prognostic value in patients with bone metastases is unknown. We investigated this question in patients with bone metastases secondary to prostate cancer and to...

RESPONSE: Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer (2005)

Saad, Fred

RESPONSE: Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma (2004)

Saad, Fred

RESPONSE: Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer (2004)

Saad, Fred

RESPONSE: Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma (2003)

Saad, Fred

RESPONSE: Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma (2003)

Saad, Fred, Gleason, Donald M., Murray, Robin, Goas, J. Allen, Chen, Bee

Bisphosphonates in Prostate Cancer: Where Are We and Where Should We Go? (2003)

Saad, Fred

A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma (2002)

Saad, Fred, Gleason, Donald M., Murray, Robin, Tchekmedyian, Simon, Venner, Peter, Lacombe, Louis, ...

Background: Bone metastases are a common cause of morbidity in patients with prostate carcinoma. We studied the effect of a new bisphosphonate, zoledronic acid, which blocks bone destruction, on...

Should urologists give chemotherapy?

Saad, Fred

PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice

Klotz, Laurence, Saad, Fred

Ebp1 expression in benign and malignant prostate

Gannon, Philippe O, Koumakpayi, Ismaël Hervé, Le Page, Cécile, Karakiewicz, Pierre I, Mes-Masson, Anne-Marie, Saad, Fred

Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study

Jeldres, Claudio, Suardi, Nazareno, Perrotte, Paul, Capitanio, Umberto, Walz, Jochen, Hutterer, Georg C., ...

Preface

Saad, Fred

Diagnosis and management of benign prostatic hyperplasia in primary care

Tanguay, Simon, Awde, Murray, Brock, Gerald, Casey, Richard, Kozak, Joseph, Lee, Jay, ...

Benign prostatic hyperplasia (BPH), and its clinical manifestation as lower urinary tract symptoms (LUTS), is a major health concern for aging men. There have been significant advances in the...

Gleason grading controversies: what the chemoprevention trials have taught us

Klotz, Laurence, Drachenberg, Darrel, Fradet, Yves, Saad, Fred, Trachtenberg, John, Zlotta, Alexandre

The recent Prostate Chemoprevention Trial (PCPT), which assessed the efficacy of finasteride in reducing prostate cancer incidence, showed promising results. However, patients who developed cancer...